News

Wall Street analysts warn that if Sarepta Therapeutics doesn't resolve the Elevidys issues, it could jeopardize its ability to repay debt in 2027.
Sarepta shares dropped 27% after the first death in March. BMO lowered its price target to $70, warning of risks to 2025 revenue guidance and potential regulatory action affecting non-ambulatory ...
The Sarepta agreement reduces financial risk and lends credence to Arrowhead's platform. Within this context, Arrowhead appears conservatively valued, at a market capitalization near $2.75 ...